ATE354098T1 - Screening-verfahren - Google Patents

Screening-verfahren

Info

Publication number
ATE354098T1
ATE354098T1 AT99961418T AT99961418T ATE354098T1 AT E354098 T1 ATE354098 T1 AT E354098T1 AT 99961418 T AT99961418 T AT 99961418T AT 99961418 T AT99961418 T AT 99961418T AT E354098 T1 ATE354098 T1 AT E354098T1
Authority
AT
Austria
Prior art keywords
salt
slc
mch
screening
appetite
Prior art date
Application number
AT99961418T
Other languages
English (en)
Inventor
Masaaki Mori
Yukio Shimomura
Shiro Takekawa
Tsukasa Sugo
Yoshihiro Ishibashi
Chieko Kitada
Nobuhiro Suzuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27314502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE354098(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE354098T1 publication Critical patent/ATE354098T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
AT99961418T 1998-12-28 1999-12-27 Screening-verfahren ATE354098T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP37445498 1998-12-28
JP12268899 1999-04-28
JP24930099 1999-09-02

Publications (1)

Publication Number Publication Date
ATE354098T1 true ATE354098T1 (de) 2007-03-15

Family

ID=27314502

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99961418T ATE354098T1 (de) 1998-12-28 1999-12-27 Screening-verfahren

Country Status (9)

Country Link
US (1) US6991908B1 (de)
EP (1) EP1143000B1 (de)
KR (1) KR20020008111A (de)
CN (1) CN1344321A (de)
AT (1) ATE354098T1 (de)
AU (1) AU1802000A (de)
CA (1) CA2356412A1 (de)
DE (1) DE69935159T2 (de)
WO (1) WO2000040725A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
WO2000070347A1 (en) * 1999-05-19 2000-11-23 Astrazeneca Ab Assays for agonists, agonists and inverse agonists of melanin concentrating hormone (mch) binding to the somatostatin-like receptor (slc-1)
US7198910B1 (en) 1999-07-14 2007-04-03 Merck & Co., Inc. Nucleic acid encoding melanin-concentrating hormone receptor
CA2407149C (en) * 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
JP4780365B2 (ja) * 2000-07-05 2011-09-28 武田薬品工業株式会社 Ｍｃｈ受容体アンタゴニスト・アゴニストのスクリーニング方法
AU2001269440A1 (en) 2000-07-05 2002-01-14 Takeda Chemical Industries Ltd. Method for screening mch receptor antagonist/agonist
US7078187B2 (en) 2001-04-19 2006-07-18 Neurogen Corporation Melanin concentrating hormone receptors
US7078484B2 (en) 2001-04-19 2006-07-18 Neurogen Corporation Melanin concentrating hormone receptors
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
CN101134757A (zh) 2002-11-06 2008-03-05 安姆根有限公司 稠合杂环化合物
AU2004266233A1 (en) 2003-08-13 2005-03-03 Amgen, Inc. Melanin concentrating hormone receptor antagonist
WO2008001778A1 (fr) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Animal génétiquement modifié et son utilisation
US11614893B2 (en) 2010-09-15 2023-03-28 Pure Storage, Inc. Optimizing storage device access based on latency
WO2016133374A1 (ko) * 2015-02-17 2016-08-25 싸이퍼롬, 인코퍼레이티드 자궁수축억제제 부작용 방지를 위한 개인별 단백질 손상 정보 기반의 자궁수축억제제 선택 방법
CN111443209B (zh) * 2020-03-26 2022-12-20 中国中医科学院医学实验中心 一种筛选非激动剂型PPARγ配体的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049655A (en) * 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
EP0668930B1 (de) * 1991-10-01 2002-12-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Ein verfahren zur identifikation von liganden und ligandantagonisten
FR2687680A1 (fr) * 1992-02-20 1993-08-27 Centre Nat Rech Scient Procede de marquage de proteines et de peptides par acylation de leur fonction alpha aminee par un reactif comportant une fonction carboxylique activee.
JPH08193099A (ja) * 1994-11-14 1996-07-30 Takeda Chem Ind Ltd 新規ｇ蛋白質共役型レセプター蛋白質、その製造法および用途
WO1996018651A1 (en) * 1994-12-16 1996-06-20 Smithkline Beecham Corporation Human somatostatin-like receptor
US5849708A (en) * 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
US20020038007A1 (en) * 1996-12-11 2002-03-28 Ames Robert S. Method of finding agonist and antagonist to human 11cb splice variant
EP0848060A3 (de) * 1996-12-11 2000-02-02 Smithkline Beecham Corporation Humane 11CB Splice-Varianten
IL130880A (en) * 1997-04-14 2004-03-28 Arena Pharm Inc Method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
WO1998052554A1 (en) * 1997-05-23 1998-11-26 Bristol-Myers Squibb Company Spirocyclopropyl fluorenes as melatonergic agents
WO1999028492A1 (en) 1997-12-03 1999-06-10 Smithkline Beecham Corporation A method of finding agonist and antagonist to human 11cb splice variant
US6221613B1 (en) * 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

Also Published As

Publication number Publication date
DE69935159T2 (de) 2007-10-25
CN1344321A (zh) 2002-04-10
WO2000040725A1 (en) 2000-07-13
US6991908B1 (en) 2006-01-31
AU1802000A (en) 2000-07-24
EP1143000A4 (de) 2005-01-12
CA2356412A1 (en) 2000-07-13
DE69935159D1 (de) 2007-03-29
EP1143000A1 (de) 2001-10-10
KR20020008111A (ko) 2002-01-29
EP1143000B1 (de) 2007-02-14

Similar Documents

Publication Publication Date Title
ATE354098T1 (de) Screening-verfahren
FI974173A (fi) Endoteliiniantagonisteja ja endoteliinisyntaasi-inhibiittoreita kohdunsupistussairauksien, raskausmyrkytyksen esivaiheen, valtimon haurausk ovetustaudin ja verenpainetaudin ennaltaehkäisemiseksi ja hoitamiseksi sekä hormonipalautusterapiaan
NO984513D0 (no) Benzyl(iden)-laktam-derivater, deres fremstilling og deres anvendelse som selektive (ant)agonister for 5-HT1A- og 5-HT1D-reseptorer
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
DE69833699D1 (de) Gefässverschliessende Vorrichtung zur Behandlung von Aneurismen
BR9908269A (pt) Método e aparelho para proporcionar um ajuste de tempo para um sistema de comunicação sem fio
ATE250575T1 (de) Ep4 rezeptor selektive agonisten zur behandlung der osteoporose
DE60035840D1 (de) Chirurgische Vorrichtung zum Anbringen von resorbierbaren Nieten / Stangen
BR9304376A (pt) Coxim higiênico interlabial, e processo para fazer dispositivo de proteção higiênica
IT7850944A0 (it) Perfezionamento negli imballi per suture oftalmiche
WO2001080788A3 (en) Method and apparatus for creating intrauterine adhesions
WO2004045422A3 (en) Deployable constrictor for uterine artery occlusion and introduction device
FR2559383B1 (fr) Dispositif de mise en forme pour tampon hygienique
IS2691B (is) Áætlun um lyfjaskammta og lyfjasamsetningar til getnaðarvarnar í neyð
BR9001807A (pt) Embalagem de sutura cirurgica
DK164555C (da) 1-(4-aminofenyl)-4-metyl-7,8-metylendioxy-3,4-dihydro-5h-2,3-benzodiazepin, syreadditionssalte deraf, fremgangsmaade til fremstilling heraf samt farmaceutiske praeparater med cns-stimulerende virkning indeholdende saadanne forbindelser
BR9007098A (pt) Dispositivo contraceptivo intra-uterino
FR2746292B1 (fr) Agrafe chirurgicale, dispositif pour sa mise en oeuvre, et agrafeuse correspondante
WO1999020223A3 (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
FR2637858B1 (fr) Maitre-cylindre de freinage, methode de reglage du maitre-cylindre et dispositif pour la mise en oeuvre de la methode
EP1034002A4 (de) Verfahren zur inhibierung eines vorzeitigen reissens der fötalen membran, reifung der uteruscervix sowie vorbereitende arbeiten
Goldman et al. Primary abdominal pregnancy: can artificial abortion, endometriosis and IUD be etiological factors?
AU1285292A (en) Process and apparatus for extended, non-invasive monitoring of uterine contractions
Chien et al. Repeated ectopic pregnancy on the tubal stump after laparoscopic salpingectomy
UA32373A (uk) Спосіб реабілітації жінок, які перенесли атонічні маткові кровотечі з акушерською гістеректомією

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties